Definium Therapeutics Operating Income Over Time
| DFTX Stock | 16.23 1.12 6.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Definium Therapeutics Performance and Definium Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Definium Therapeutics. Projected growth potential of Definium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Definium Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Definium Therapeutics is measured differently than its book value, which is the value of Definium that is recorded on the company's balance sheet. Investors also form their own opinion of Definium Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Definium Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Definium Therapeutics' market value can be influenced by many factors that don't directly affect Definium Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Definium Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Definium Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Definium Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Definium Therapeutics and related stocks such as Plaza Retail REIT, Caseys General Stores, and Capital Clean Energy Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CASY | 11.6 M | 215.2 M | 198.9 M | 233.6 M | 323.2 M | 388.9 M | 311.2 M | 265.4 M | 319.1 M | 395.5 M | 454 M | 497.7 M | 639.3 M | 709.6 M | 796.4 M | 915.9 M | 961.7 M |
| CCEC | 11.2 M | 35.3 M | 45.1 M | 48.4 M | 60.7 M | 73.8 M | 75.7 M | 67.6 M | 39.3 M | 40.1 M | 47.2 M | 71.2 M | 135.4 M | 150.8 M | 191.1 M | 219.8 M | 230.8 M |
| PLTK | 246.6 M | 246.6 M | 246.6 M | 246.6 M | 246.6 M | 246.6 M | 164.5 M | 333.1 M | 432.6 M | 497.4 M | 387.2 M | 562.2 M | 471.4 M | 501.6 M | 391.6 M | 450.3 M | 438.7 M |
| ASO | 157.3 M | 157.3 M | 157.3 M | 157.3 M | 157.3 M | 157.3 M | 157.3 M | 157.3 M | 128.9 M | 179.4 M | 420.4 M | 907.9 M | 846.5 M | 677.9 M | 538.6 M | 619.4 M | 530.3 M |
| MCD | 856.9 M | 8.5 B | 8.6 B | 8.8 B | 7.9 B | 7.1 B | 7.7 B | 9.6 B | 8.8 B | 9.1 B | 7.3 B | 10.4 B | 9.4 B | 11.6 B | 11.7 B | 13.5 B | 14.1 B |
Definium Therapeutics and related stocks such as Plaza Retail REIT, Caseys General Stores, and Capital Clean Energy Operating Income description
Operating Income is the amount of profit realized from Definium Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Definium Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Definium Therapeutics | DFTX |
Specialization | Healthcare, Biotechnology |
| Business Address | One World Trade |
| Exchange | NASDAQ Exchange |
null 16.23
Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.